This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

MannKind: Great Trade; Good Investment?

CHARLOTTE, N.C. ( Stockpickr) -- On Aug. 14, MannKind ( MNKD) reported long-awaited positive phase III results from two clinical trials of its Afrezza insulin and inhaler product. Now the company finds itself faced with a fascinating mixture of positives, negatives and uncertainties, guaranteeing that MNKD will be an excellent trading stock -- with the whipsaw price-movements so dearly loved by traders -- for the foreseeable future.

>>5 Stocks Poised for Breakouts

But couldn't MNKD also represent an exceptional investment right now, as well?

Let's look at it from both angles, after neatly categorizing the positives, negatives and uncertainties.


1. Clinical trials for both type 1 and type 2 diabetes patients met the primary endpoints sought by the company and, presumably, the FDA.

2. Afrezza, by itself or in combination with an oral insulin product, was well-tolerated by nearly 100% of participating patients.

3. The trials showed that Afrezza, by itself or in combination with an oral insulin product, may well reduce or eliminate many diabetics' reliance on injected insulin.

4. As the FDA has, in the past, already approved Exubera -- widely perceived to be an inferior product compared to Afrezza -- FDA approval of Afrezza in early 2014 should be a near-certainty.

>>4 Biotech Stocks Under $10 Making Big Moves

5. Exubera was pulled by Pfizer ( PFE) in 2007, so if approved by the FDA, Afrezza will hold an absolute monopoly on the inhaled-insulin market, which many believe to be initially worth $3 billion yearly.


1. Approximately one-third of patients participating in the Afrezza clinical trials experienced, as a side effect, a mild cough and a slightly lessened exhaling power of the lungs.

2. A greater number of Afrezza patients experienced low blood sugar, compared with patients using injected insulin.

3. Doctors have for many decades been totally familiar with the use and prescribing of injected insulin. Afrezza will be totally new to them, with regards to dosage, performance, side effects and so on.

4. Exubera, Pfizer's inhaled-insulin product previously approved by the FDA, proved to be a commercial failure, losing $3 billion for that company and leading them to pull out of the market after only one year. Many fear that AFREZZA may suffer a similar lack of commercial success.
1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
LLY $75.53 0.00%
MNKD $1.35 0.00%
PFE $32.71 0.00%
SNY $41.10 0.00%
AAPL $93.74 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs